{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:36:32Z","timestamp":1789475792753,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>\n                      Recurrent somatic mutations in the\n                      <jats:italic toggle=\"yes\">JAK2,<\/jats:italic>\n                      calreticulin (\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      ), and the\n                      <jats:italic toggle=\"yes\">MPL<\/jats:italic>\n                      genes are described as drivers of\n                      <jats:italic toggle=\"yes\">BCR-ABL1<\/jats:italic>\n                      -negative myeloproliferative neoplasms (MPN) that includes polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PMF), and MPN unclassified (MPN-U).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We describe the mutation profile and clinical features of MPN cases diagnosed at a tertiary care center.\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      V617F and MPL (S505\/W515) mutations were screened by allele-specific polymerase chain reaction, while\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      exon 9 and\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      exon 12 mutations were screened by fragment analysis\/Sanger sequencing. Among the 1,570 patients tested for these mutations during the study period, 407 were classified as MPN with a diagnosis of PV, ET, PMF, and MPN-U seen in 30%, 17%, 36%, and 17%, respectively, screened.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Similar to previous reports from Asian countries, the incidence of PMF was the highest among the classic MPN. JAK2V617F mutation was detected in 90% of PV, 38% of ET, 48% of PMF, and 65% of MPN-U.\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      exon 12 mutations were seen in 5.7% of PV and 1.4% of PMF.\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      exon 9 mutations were seen in 33% of ET, 33% of PMF, and 12% of MPN-U.\n                      <jats:italic toggle=\"yes\">MPL<\/jats:italic>\n                      mutations were detected in 2.8%, 2.7%, and 2.9% of ET, PMF, and MPN-U, respectively. Fifteen % of PMF, 26% of ET, and 22% of MPN-U were triple negative.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      There was a significantly higher incidence of\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      mutation in PMF and ET cases. Our study highlights the challenges in the diagnosis of\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      -negative PV and the need for harmonization of criteria for the same.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T02:35:47Z","timestamp":1616207747000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms"],"prefix":"10.4103","volume":"15","author":[{"given":"Madhavi","family":"Maddali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Kumar","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lionel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Therese","family":"Manipadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup J.","family":"Devasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Korula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Fouzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonkuzhali","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20241211","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of myeloproliferative neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J Clin Oncol"},{"key":"R2-3-20241211","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic Options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R3-3-20241211","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R4-3-20241211","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R5-3-20241211","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00277-020-04004-7","article-title":"JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis","volume":"99","author":"Maddali","year":"2020","journal-title":"Ann Hematol"},{"key":"R6-3-20241211","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"R7-3-20241211","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-3-20241211","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1002\/cam4.3004","article-title":"MERGE: A multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria","volume":"9","author":"Yassin","year":"2020","journal-title":"Cancer Med"},{"key":"R10-3-20241211","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"R11-3-20241211","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"key":"R12-3-20241211","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"R13-3-20241211","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"R14-3-20241211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12288-018-0982-5","article-title":"Allele specific PCR: a cost effective screening method for MPL mutations in myeloproliferative neoplasms","volume":"34","author":"Arunachalam","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R15-3-20241211","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"R16-3-20241211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"R17-3-20241211","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"R18-3-20241211","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"R19-3-20241211","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"R20-3-20241211","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR -mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"R21-3-20241211","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"R22-3-20241211","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"R23-3-20241211","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/modpathol.2016.182","article-title":"The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations","volume":"30","author":"Gianelli","year":"2017","journal-title":"Mod Pathol"},{"key":"R24-3-20241211","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"R25-3-20241211","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms","volume":"143","author":"Kim","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"R26-3-20241211","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2 V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"R27-3-20241211","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.13047","article-title":"The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera","volume":"167","author":"Ancochea \u00c0, \u00c1lvarez-Larr\u00e1n","year":"2014","journal-title":"Br J Haematol"},{"key":"R28-3-20241211","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/IJPM.IJPM_223_17","article-title":"Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India","volume":"61","author":"Rabade","year":"2018","journal-title":"Indian J Pathol Microbiol"},{"key":"R29-3-20241211","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"R30-3-20241211","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1179\/1607845415Y.0000000018","article-title":"Calreticulin mutation profile in Indian patients with primary myelofibrosis","volume":"20","author":"Sazawal","year":"2015","journal-title":"Hematology"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:31Z","timestamp":1787838031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.03.002"}},"subtitle":["A Single-Center Experience From India"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2021.03.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}